Fundz

Solid Biosciences Inc. reported raising $40 Million in an initial SEC Form D filing, from an offering of $40 Million

PUBLIC · SLDBOct 26, 2020

Amount Raised

$40 Million

$40 Million sold, per SEC Form D (first sale Oct 26, 2020)

Round Type

Venture

CharlestownBiotechnologyHealthcareHealth CareGeneticsTherapeutics

Who else raised in Healthcare and Genetics around the same time

Companies in the same sectors as Solid Biosciences that raised within 45 days of this round, from Fundz verified event records.

Who to call at Solid Biosciences, and when

A new round usually means Solid Biosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Solid Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Solid Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Solid Biosciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Solid Biosciences

Location

500 RUTHERFORD AVENUE

Charlestown, Massachusetts, United States

About

Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for the treatment of Friedreich’s ataxia, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Solid Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Solid Biosciences's next move

See what Strategic adds

Solid Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.